Dr. Mitchell Jones has been with the company since its inception and is the driving force behind Micropharma’s innovation and R&D. He has pioneered novel probiotic selection assays and methods for development which form the basis for the company’s rapidly growing product pipeline. Dr. Jones is well published in peer reviewed journals and has submitted 40 patent applications. Dr. Jones has been instrumental in raising public research support and has secured two successful NRC-IRAP applications awarded to the Company in 2008 for the development of a microencapsulated nitric oxide producing agent containing topical medical device and in 2011 for the development of an oral bacterial formulation for the treatment of diabetes and pre-diabetes. Further, he has successfully collaborated and sponsored four NSERC Engage grants with academic researchers in various fields of natural science and engineering. Dr. Jones was trained at McGill University where he holds degrees in Human Physiology (BSc), Biomedical Engineering (MEng and PhD) as well as in Clinical Medicine (MD). Throughout his career, Dr. Jones has been the recipient of several prestigious awards for excellence in academics, research and innovation including the Alexander Graham Bell Scholarship, Geddes Prize in Biomedical Engineering, Dean’s Honor List, NSERC PGSA Postgraduate Scholarship, and Martlett Scholarship.
Ryan Jones has a ten year track record of successful experience as an entrepreneur. Since Micropharma’s inception in 2002, he has been the leading force behind Micropharma’s strategic and business direction as CEO. Jones led the acquisition of the company’s initial intellectual property from McGill University, attracted the Board of Directors and is responsible for three successful rounds of financing. He has also been highly involved in business development and industry partnering. Prior to Micropharma, Mr. Jones worked on a number of other successful entrepreneurial ventures. He has worked for companies such as Johnson Controls and Ritz-Carlton where he was responsible for securing over US$300 million while managing sales, marketing, and public relations. Jones holds a bachelor’s degree in mechanical engineering from McGill University.
Dr. Prakash is a professor of Biomedical Engineering in the Faculty of Medicine at McGill University and is a member of McGill’s Biomedical Technology and Cell Therapy Research Laboratory and Artificial Cells and Organs Research, and Experimental Medicine departments. Dr. Prakash has published more than 225 peer reviewed articles/abstracts, been listed as an inventor in 52 approved/pending patents. He is the winner of 28 awards and his research has generated multi millions in individual and collective research grants. Currently his team is conducting major research in the areas of probiotics, microencapsulation, nanoencapsulation, artificial cells, drug targeting, siRNA, cell delivery, nanomedicine, kidney substitutes, and their use for a number of diseases. Dr. Prakash holds a B.Sc. (H), M.Sc., M. Tech., Ph.D. and D.Sc.
Dr. Chris Wahl brings knowledge, experience, and direction on product development, strategy and commercialization. Dr. Wahl joined Micropharma from McKinsey and Company, where he worked in the Pharmaceutical and Medical Products Practice as a consultant to Pharmaceutical, Medical Device and Biotechnology companies. While at McKinsey, he worked on multiple product strategies including product development, launch, lifecycle management and loss of exclusivity. He also has experience in marketing and sales force strategy and design. In addition to his client work at McKinsey he was also involved in firm-knowledge initiatives including serving as a firm Knowledge Expert on osteoarthritis, serving on the Diabetes Standard Therapeutic Area Team and leading firm coverage of the stem cell industry. Prior to McKinsey, Dr. Wahl worked at Merck Frosst Canada. Dr. Wahl holds an MBA from McGill University, an MD from McGill University, a B.Sc. in Accounting from Washington & Lee University, and a B.A. in Biology from Washington & Lee University.
Gordon Hammond brings to the Board a lifetime of experience as an entrepreneur, commencing during his post secondary education in England and continuing after his emigration to Canada in 1967. In recent years, Mr. Hammond’s focus has shifted from purely commercial initiatives to the cultural sector, where his keen interest in heritage runs the gamut from leadership to research, fundraising to strategic planning, governance to marketing. As Chair of the Board of Micropharma, Mr. Hammond’s diverse background and focus is well suited to the needs of a young entrepreneurial company whose current and future strength lies in combining the skill and ingenuity of its scientists and managers with the seasoned business guidance of its Board and advisors.
Borys Chabursky is a graduate of Harvard Business School and is the President and Founder of SHI Consulting and the Chairman of SHI Capital, the largest life-science consulting firm in Canada. As president, Mr. Chabursky oversees all aspects of strategy and capital raising for SHI’s clients in the life sciences sector. He specializes in strategic planning, capital sourcing and business development for private and public biotech companies, as well as medical device, nutraceutical and pharmaceutical companies. In the past ten years, he has worked closely with industry leaders, Top 10 pharmaceutical companies, government, hospitals and health care networks. He also provided interim management for 7 start-ups and has provided angel financing to 15 start-ups. Mr. Chabursky was named one of Canada’s “Top 40 under 40” in 2002 and he is also a member of the Young Presidents’ Organization (YPO).
Mr. Semmens is a private investor who is currently involved with start-up companies in energy, biotech and information technology. He is a member of NYC Angels, and also a Professor of Finance at the Leonard N. Stern School of Business at New York University. He currently serves on the Board of Directors of CGG-Veritas, a Paris bourse and NYSE listed company and of Bronco Holdings LP. From 1993 until 2000 when the company was sold, Mr. Semmens was a General Partner of the Beacon Group, a private investment and advisory firm, where he managed two private equity funds concentrated on the energy business. Prior to co-founding The Beacon Group, he was with the investment banking division of Goldman, Sachs & Co. where he concentrated in corporate finance, private equity and commodity derivatives. He holds law and MBA degrees from Northwestern University.
Mr. Greenberg is president of Insurance and Investment Planning Consultants. He has 25 years of experience in the areas of insurance, employee benefits and financial planning. Jeff has also served on the board of directors for several companies, most recently and notably a New Jersey based financial institution, Crown Bank, with assets over $100 million. Jeff has a track record of successful business experience with a concentration in finance. He is an active angel investor for start up companies, is the host of several annual seminars where he consults business executives on financial planning, and brings a wealth of experience to the Micropharma Limited team. Jeff and his wife are parents of three.
Mathieu has a background in finance and is the Head of Strategy and Development for Groupe Danone’s Medical Nutrition Division after having spent most of his career with Danone’s Mergers and Acquisitions team. Mathieu has an MBA from ESADE in France and HEC School of management.
Maurits Cuypers is Director Innovation & Partnership at Groupe Danone's fresh dairy division. He works with Danone's research & development teams to find, create, develop and manage collaborative innovation opportunities and has spend most of his career in the purchasing team. Maurits holds a Master of Science degree in mechanical engineering from the Delft University of Technology in Holland.